Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

被引:0
|
作者
Sestak, Ivana
Regan, Meredith
Dodson, Andrew
Viale, Giuseppe
Thurlimann, Beat
Colleoni, Marco
Cuzick, Jack
Dowsett, Mitch
机构
[1] QMUL, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ralph Lauren Ctr Breast Canc Res, London, England
[4] European Inst Oncol, Milan, Italy
[5] Kantonsspital St Gallen, St Gallen, Switzerland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
GS6-01
引用
下载
收藏
页数:1
相关论文
共 50 条
  • [21] Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice
    Badr, Nahla M.
    Spooner, David
    Steven, Jane
    Stevens, Andrea
    Shaaban, Abeer M.
    HISTOPATHOLOGY, 2021, 79 (01) : 47 - 56
  • [22] A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer
    Skliris, Georgios P.
    Nugent, Zoann J.
    Rowan, Brian G.
    Penner, Carla R.
    Watson, Peter H.
    Murphy, Leigh C.
    ENDOCRINE-RELATED CANCER, 2010, 17 (03) : 589 - 597
  • [23] DISTANT RECURRENCES AT MEDIAN OF 5-YEARS AMONG 9.779 POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER TREATED ON THE TEAM TRIAL OF ADJUVANT ENDOCRINE THERAPY
    Nortier, H.
    Hille, E.
    Rea, D.
    Seynaeve, C.
    Hasenburg, A.
    Vannetzel, J.
    Dirix, L.
    Markopoulos, C.
    van de Velde, C.
    Jones, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 78 - 78
  • [24] Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence
    Moon, Gilseong
    Noh, Hany
    Cho, In-Jeong
    Lee, Jong-in
    Han, Airi
    BREAST CANCER, 2020, 27 (01) : 54 - 61
  • [25] Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence
    Gilseong Moon
    Hany Noh
    In-Jeong Cho
    Jong-in Lee
    Airi Han
    Breast Cancer, 2020, 27 : 54 - 61
  • [26] Using CTS5 Calculator to Predict The 5-10-Year Risk of Late Distant Recurrence for Women With ER-Positive Breast Cancer Who Are Recurrence-Free 5 Years After Endocrine Therapy and To Reduce the Number of Patients Needing Discussion for The Extended Endocrine Therapy in The Breast MDTs: A Quality Improvement Project
    Ahmed, S.
    Kiruparan, P.
    Debnath, D.
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [27] Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
    Mark Laible
    Kerstin Hartmann
    Claudia Gürtler
    Tobias Anzeneder
    Ralph Wirtz
    Stephan Weber
    Thomas Keller
    Ugur Sahin
    Martin Rees
    Annette Ramaswamy
    BMC Cancer, 19
  • [28] Distant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres
    Doughty, J. C.
    Mansell, J.
    Monypenny, I.
    Skene, A.
    Abram, P.
    Carpenter, R.
    Gattuso, J.
    Wilson, C.
    Angerson, W.
    BREAST, 2009, 18 : S66 - S66
  • [29] Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
    Laible, Mark
    Hartmann, Kerstin
    Guertler, Claudia
    Anzeneder, Tobias
    Wirtz, Ralph
    Weber, Stephan
    Keller, Thomas
    Sahin, Ugur
    Rees, Martin
    Ramaswamy, Annette
    BMC CANCER, 2019, 19 (1)
  • [30] Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?
    K.L. Cheung
    R.I. Nicholson
    R.W. Blamey
    J.F.R. Robertson
    Breast Cancer Research and Treatment, 2001, 65 : 155 - 162